Tony Wood, GSK R&D chief
February 14, 2023 07:30 AM ESTUpdated 08:12 AM
Deals
R&D
Coronavirus

GSK re­vis­es Covid deal with Vir, pulls out of next-gen work

Amber Tong

GSK is tak­ing an axe to an­oth­er of Hal Bar­ron’s lega­cy pacts, end­ing a col­lab­o­ra­tion with Vir Biotech­nol­o­gy work­ing on new an­ti­bod­ies and vac­cines against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times